John Posner

3.0k total citations
80 papers, 2.0k citations indexed

About

John Posner is a scholar working on Physiology, Oncology and Psychiatry and Mental health. According to data from OpenAlex, John Posner has authored 80 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Physiology, 16 papers in Oncology and 16 papers in Psychiatry and Mental health. Recurrent topics in John Posner's work include Migraine and Headache Studies (10 papers), HER2/EGFR in Cancer Research (8 papers) and Herpesvirus Infections and Treatments (8 papers). John Posner is often cited by papers focused on Migraine and Headache Studies (10 papers), HER2/EGFR in Cancer Research (8 papers) and Herpesvirus Infections and Treatments (8 papers). John Posner collaborates with scholars based in United Kingdom, United States and Japan. John Posner's co-authors include P. Rolan, R Wootton, Emma J. Seaber, N.T. On, A. B. Bennett, Ziad Hussein, A. W. Peck, John P. Griffin, Richard Peck and PE Rolan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Pain.

In The Last Decade

John Posner

79 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Posner United Kingdom 26 455 386 382 302 283 80 2.0k
Manuel Román Spain 25 300 0.7× 201 0.5× 274 0.7× 228 0.8× 175 0.6× 116 1.9k
Francisco Abad‐Santos Spain 31 493 1.1× 314 0.8× 421 1.1× 527 1.7× 233 0.8× 220 3.3k
Martin Bauer Austria 28 545 1.2× 283 0.7× 787 2.1× 361 1.2× 320 1.1× 100 2.4k
Yoshiyuki Kagawa Japan 25 385 0.8× 116 0.3× 447 1.2× 596 2.0× 157 0.6× 150 1.9k
D Müller Germany 32 723 1.6× 377 1.0× 256 0.7× 1.1k 3.5× 152 0.5× 86 3.5k
Keri Wellington New Zealand 26 172 0.4× 120 0.3× 148 0.4× 329 1.1× 208 0.7× 54 1.9k
Inge De Lepeleire United States 28 237 0.5× 480 1.2× 101 0.3× 278 0.9× 147 0.5× 80 2.4k
Chun‐Jung Lin Taiwan 28 194 0.4× 149 0.4× 350 0.9× 530 1.8× 311 1.1× 110 2.8k
Janet K. Coller Australia 28 140 0.3× 290 0.8× 426 1.1× 505 1.7× 123 0.4× 78 2.4k
Michel Lemaire Japan 28 169 0.4× 107 0.3× 699 1.8× 619 2.0× 147 0.5× 62 2.4k

Countries citing papers authored by John Posner

Since Specialization
Citations

This map shows the geographic impact of John Posner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Posner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Posner more than expected).

Fields of papers citing papers by John Posner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Posner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Posner. The network helps show where John Posner may publish in the future.

Co-authorship network of co-authors of John Posner

This figure shows the co-authorship network connecting the top 25 collaborators of John Posner. A scholar is included among the top collaborators of John Posner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Posner. John Posner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sullivan, Richard, et al.. (2023). Revitalising cancer trials post-pandemic: time for reform. British Journal of Cancer. 128(8). 1409–1414. 2 indexed citations
2.
Goncalves, Maria B., Tim Mant, Jörg Täubel, et al.. (2023). Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants. British Journal of Clinical Pharmacology. 89(12). 3573–3583. 4 indexed citations
3.
Ferro, Albert, et al.. (2023). Serum amyloid A—A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19. Frontiers in Medicine. 10. 1135695–1135695. 12 indexed citations
4.
Macpherson, Iain R., Pavlina Spiliopoulou, Saeed Rafii, et al.. (2019). A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research. 22(1). 1–1. 48 indexed citations
5.
Harding, Cary O., Roberto Amato, Nicola Longo, et al.. (2018). Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. PMC. 1 indexed citations
6.
Arkenau, Hendrik‐Tobias, Antoîne Italiano, Gabriel Mak, et al.. (2018). An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer. 103. 17–23. 10 indexed citations
7.
Deva, Sanjeev, Richard D. Baird, Nicola Cresti, et al.. (2015). Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.. Journal of Clinical Oncology. 33(15_suppl). 2511–2511. 5 indexed citations
8.
Spicer, James, Richard D. Baird, Aneta Suder, et al.. (2014). Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. European Journal of Cancer. 51(2). 137–145. 13 indexed citations
9.
Calder, Nicole, Malcolm Boyce, John Posner, & David Sciberras. (2003). Clinical pharmacology studies in UK Phase 1 units: an AHPPI survey 1999–2000. British Journal of Clinical Pharmacology. 57(1). 76–79. 3 indexed citations
10.
Peck, Richard, Emma J. Seaber, Ruth Dixon, et al.. (1998). The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women*. Clinical Pharmacology & Therapeutics. 63(3). 342–353. 30 indexed citations
11.
12.
Seaber, Emma J., N.T. On, Ruth Dixon, et al.. (1997). The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). British Journal of Clinical Pharmacology. 43(6). 579–587. 52 indexed citations
13.
Hussein, Ziad & John Posner. (1997). Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. British Journal of Clinical Pharmacology. 43(5). 457–465. 109 indexed citations
14.
Seaber, Emma J., et al.. (1996). The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. British Journal of Clinical Pharmacology. 41(2). 141–147. 52 indexed citations
15.
Peck, Richard, R Wootton, Peter Crome, et al.. (1996). Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine*. Clinical Pharmacology & Therapeutics. 59(1). 22–31. 7 indexed citations
16.
Davis, John D., et al.. (1996). Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. British Journal of Clinical Pharmacology. 42(2). 246–248. 3 indexed citations
17.
18.
Posner, John & Christine Burke. (1985). The effects of naloxone on opiate and placebo analgesia in healthy volunteers. Psychopharmacology. 87(4). 468–472. 32 indexed citations
19.
Bennett, A. B. & John Posner. (1971). Studies on prostaglandin antagonists. British Journal of Pharmacology. 42(4). 584–594. 121 indexed citations
20.
Posner, John. (1969). The inhibitory innervation of the bovine iris sphincter.. PubMed. 37(2). 515P–516P. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuel Román Breakdown of academic impact, for papers by Francisco Abad‐Santos Breakdown of academic impact, for papers by Martin Bauer Breakdown of academic impact, for papers by Yoshiyuki Kagawa Breakdown of academic impact, for papers by D Müller Breakdown of academic impact, for papers by Keri Wellington Breakdown of academic impact, for papers by Inge De Lepeleire Breakdown of academic impact, for papers by Chun‐Jung Lin Breakdown of academic impact, for papers by Janet K. Coller Breakdown of academic impact, for papers by Michel Lemaire
Rankless by CCL
2026